BioSpace News Archive

State’s largest health plan expands to better serve one of the largest retirement communities in the nation

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that RGN-137, the Company’s wound healing product candidate currently the subject of a U.S. clinical trial,

LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced eight new client partnerships, additional hires and the launch of an investor relations thought leadership series.

Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease

Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the second quarter ended June 30, 2019.

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Brian Stuglik, a member of the Board of Directors, has been named Chief Executive Officer (CEO).

Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced today 510(k) clearance of the PrisMax system and integrated TherMax blood warmer, the company’s next-generation platform for continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE).

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended June 30, 2019.

Special ticket package includes donation to support prostate cancer research

Select Medical Holdings Corporation (“Holdings”) (NYSE: SEM), today announced that Select Medical Corporation (“Select”) has priced its private placement of $550.0 million aggregate principal amount of its 6.250% senior notes due 2026